Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis

NCT06398652 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

336

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

BIOLOGICAL: CMAB015
BIOLOGICAL: Secukinumab

Sponsor

Taizhou Mabtech Pharmaceutical Co.,Ltd